The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface.

Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.

Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.

The present invention relates to compositions and methods for treating diseases and/or disorders associated with protein aggregates. By expressing a chimeric antigen receptor (CAR) in a monocyte, macrophage or dendritic cell, the modified cell is recruited or applied to the tissue microenvironment where it acts as a potent immune effector by infiltrating the tissue and eliminating, reducing, inhibiting or preventing protein aggregation. Other aspects of this invention include methods and pharmaceutical compositions comprising the CAR modified monocyte, macrophage or dendritic cell for treating a condition, such as a neurodegenerative disease/disorder, an inflammatory disease/disorder, a cardiovascular disease/disorder, a fibrotic disease/disorder and amyloidosis.

The present invention relates to compositions and methods for treating diseases and/or disorders associated with protein aggregates. By expressing a chimeric antigen receptor (CAR) in a monocyte, macrophage or dendritic cell, the modified cell is recruited or applied to the tissue microenvironment where it acts as a potent immune effector by infiltrating the tissue and eliminating, reducing, inhibiting or preventing protein aggregation. Other aspects of this invention include methods and pharmaceutical compositions comprising the CAR modified monocyte, macrophage or dendritic cell for treating a condition, such as a neurodegenerative disease/disorder, an inflammatory disease/disorder, a cardiovascular disease/disorder, a fibrotic disease/disorder and amyloidosis.

Compositions and methods of modulating the immune system generally involve immunomodulatory exosomes derived from platelet rich plasma subjected to multiple freeze-thaw cycles and lyophilization. In one or more embodiments, the methods involve administering the composition to a subject in an amount effective to modulate the subject's immune system. In other embodiments, the methods involve culturing a hematopoietic progenitor cell or cell differentiated from a hematopoietic progenitor cell with an immunomodulatory exosome to produce treated cells. The treated cells are then administered to the subject in an amount effective to modulate the subject's immune system.

Compositions and methods of modulating the immune system generally involve immunomodulatory exosomes derived from platelet rich plasma subjected to multiple freeze-thaw cycles and lyophilization. In one or more embodiments, the methods involve administering the composition to a subject in an amount effective to modulate the subject's immune system. In other embodiments, the methods involve culturing a hematopoietic progenitor cell or cell differentiated from a hematopoietic progenitor cell with an immunomodulatory exosome to produce treated cells. The treated cells are then administered to the subject in an amount effective to modulate the subject's immune system.

The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophages mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects.

The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophages mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects.

The present invention relate to autologous isolated unpolarized human macrophages for use in the treatment of liver disease and macrophages for use in a method of treating fibrosis in a human in need thereof.